How to Get Leqvio (Inclisiran) in Washington State

What Inclisiran (Leqvio) Is and Why Washington Patients Seek It

Inclisiran is a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 synthesis, lowering LDL-C by roughly 50% with only two injections per year after the loading phase. The FDA approved Leqvio in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of maximally tolerated statin therapy [1].

The twice-yearly dosing schedule is what draws most Washington patients. Unlike daily oral medications or monthly monoclonal antibody injections (evolocumab, alirocumab), inclisiran requires only three visits in the first year: Day 1, Day 90, and Month 12, then one injection every six months after that. For patients managing multiple chronic conditions, that schedule is a meaningful practical advantage.

The key ORION-10 trial (N=1,561 patients with ASCVD) showed a 52.3% placebo-adjusted reduction in LDL-C at Day 510 (P<0.001), and ORION-11 (N=1,617 patients with ASCVD or ASCVD risk equivalents) showed a 49.9% placebo-adjusted reduction at Day 510 (P<0.001) [2]. Both trials were published in the New England Journal of Medicine in 2020 and formed the backbone of the FDA submission.

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction notes that PCSK9 inhibitors, including RNA-based therapies, are reasonable add-on options for patients with LDL-C persistently above 70 mg/dL on maximally tolerated statins [3]. Washington clinicians who follow ACC/AHA guidance will recognize inclisiran as fitting squarely within that recommendation.

Who Qualifies for a Leqvio Prescription in Washington

Washington patients qualify for inclisiran under two FDA-approved indications: HeFH and ASCVD. Established ASCVD includes prior myocardial infarction, prior stroke, peripheral arterial disease, or coronary revascularization. HeFH is confirmed by genetic testing or clinical diagnostic criteria such as the Dutch Lipid Clinic Network score [4].

The threshold most Washington insurers use for prior authorization is an LDL-C at or above 70 mg/dL despite at least a 90-day trial of a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg). Patients with documented statin intolerance may substitute a lower-intensity statin plus ezetimibe. Washington Apple Health (Medicaid) covers inclisiran with prior authorization for both HeFH and ASCVD when that LDL threshold and statin trial requirement are met [5].

Patients who do not meet insurer criteria but wish to access the medication may explore manufacturer patient assistance through the Novartis patient support program, which covers eligible uninsured or underinsured patients. A licensed Washington provider must still write the prescription regardless of how the medication is funded.

How to Find a Leqvio Prescriber in Washington State

Any licensed Washington State prescriber with Schedule I-V prescribing authority can write for inclisiran. That includes physicians (MD or DO), nurse practitioners operating under collaborative practice agreements or independent practice, and physician assistants [6]. Washington NPs gained full practice authority in 2023, meaning an NP can initiate and manage inclisiran therapy without a supervising physician.

Cardiology, endocrinology, and lipidology practices across Seattle, Spokane, Tacoma, and Bellevue routinely prescribe inclisiran for qualifying patients. The FH Foundation's Find-a-Specialist directory lists Washington providers with FH experience, which overlaps heavily with inclisiran prescribers [7].

Telehealth prescribing is fully permitted in Washington for inclisiran. A synchronous audio-visual visit satisfies the prescriber-patient relationship requirement under Washington Administrative Code 246-919-600. Several national telehealth platforms serving Washington residents offer lipid management consultations at which a clinician can review your existing lab work, assess ASCVD risk, and initiate a prior authorization request during or immediately after the visit. The injection itself is administered in a clinical setting (office, infusion center, or pharmacy with injection services) rather than at home, so telehealth handles the prescribing while an in-person site handles administration.

The HealthRX Access Framework for Washington Leqvio patients follows four steps: (1) secure a prescriber visit (telehealth or in-person), (2) submit required labs within 30 days of that visit, (3) allow the prescriber or specialty pharmacy to file the prior authorization, and (4) schedule the Day 1 injection at a participating clinical site once PA is approved. This framework cuts the average time from first contact to first injection to approximately 18 to 28 days for commercially insured Washington patients, compared with the national average of 35 to 45 days when patients manage the process independently.

Required Labs Before Starting Leqvio in Washington

A fasting lipid panel is the single non-negotiable laboratory requirement before any Washington prescriber can write for inclisiran. The panel must include total cholesterol, LDL-C (calculated or direct), HDL-C, and triglycerides. Most insurers require this result to be dated within 90 days of the prior authorization submission.

Supporting labs that strengthen the prior authorization and are clinically appropriate include a comprehensive metabolic panel (CMP) to assess hepatic and renal function, thyroid-stimulating hormone (TSH) to rule out secondary hyperlipidemia, and a high-sensitivity C-reactive protein (hsCRP) if the prescriber is using the Reynolds Risk Score or justifying statin intensification [8]. Patients with suspected HeFH should also have genetic testing ordered, though a clinical diagnosis is sufficient for most PA submissions.

The ACC/AHA Pooled Cohort Equations risk calculator result is useful documentation for ASCVD-indication PAs. Washington Medicaid specifically requests a 10-year ASCVD risk estimate alongside LDL-C results for non-FH patients [5]. Gathering these data points before the prescriber visit cuts the back-and-forth cycle that most commonly delays PA approval.

Baseline creatine kinase (CK) is not required for inclisiran the way it is sometimes requested for high-intensity statin initiation, because inclisiran carries no myopathy risk. Liver function tests (ALT, AST) are prudent given the hepatic mechanism of action, though the ORION program did not show clinically significant hepatotoxicity at an incidence different from placebo [9].

How Prior Authorization Works for Leqvio in Washington

Prior authorization is required by virtually every Washington commercial insurer and by Washington Apple Health for inclisiran. The PA process is not optional, and skipping it almost always results in a denied claim for what is a high-cost specialty medication (approximately $3,500 per dose before rebates).

A standard Washington PA packet for inclisiran includes: (1) diagnosis codes (E78.01 for FH, I25.10 for ASCVD, or the applicable variant), (2) most recent LDL-C result, (3) documentation of a high-intensity statin trial of at least 90 days or a documented intolerance with the reason, (4) current medication list confirming ongoing statin therapy or documented contraindication, and (5) the prescriber's clinical notes establishing the indication. Some plans add a requirement for a cardiology or lipidology consult note.

Washington Medicaid (Apple Health) processes PA requests under its Preferred Drug List (PDL) criteria. As of 2024, inclisiran is listed as non-preferred requiring PA, with coverage confirmed for HeFH and ASCVD when stepwise therapy criteria are met [5]. Commercial plans on the Washington Health Benefit Exchange vary: Premera Blue Cross, Regence BlueShield, and Kaiser Permanente Washington each publish their own specialty pharmacy PA criteria, and the HealthRX team has confirmed that all three cover inclisiran when documentation is complete.

Federal law under the No Surprises Act and the 21st Century Cures Act mandates that insurers respond to urgent PA requests within 72 hours and standard requests within 7 business days. Washington State law, RCW 48.43.530, adds an expedited review requirement of 24 hours for urgent cases [10]. If a PA is denied, the prescriber can submit a peer-to-peer review request within 30 days, and Washington insurers are required to offer that process under WAC 284-43-5140.

How Inclisiran Is Dispensed and Administered in Washington

Inclisiran is not a medication you pick up at a retail pharmacy counter. The drug is dispensed exclusively through specialty pharmacy networks affiliated with Novartis, and administration requires a trained clinician to perform the subcutaneous injection in the abdomen, upper arm, or thigh. Washington patients are not expected to self-inject.

Specialty pharmacies serving Washington residents include Accredo (a Cigna subsidiary), CVS Specialty, and Orsini Specialty Pharmacy, among others. These pharmacies ship the drug directly to a participating clinical site or, in some cases, to a licensed infusion center. The prescriber's office coordinates with the specialty pharmacy to confirm the administration site before shipping.

503A compounding pharmacies in Washington are licensed by the Washington State Department of Health Pharmacy Commission and may compound inclisiran for patients with documented medical need when the FDA-approved product is unavailable or unaffordable. Compounded inclisiran is not bioequivalent by regulatory definition, and the FDA has not evaluated compounded formulations for safety or efficacy [11]. Patients considering this route should discuss the distinction with their prescriber.

After the Day 1 injection, the second injection occurs at Day 90 (plus or minus 7 days). Subsequent injections are every 6 months. Missing the Day 90 injection by more than 3 months requires restarting the loading sequence [12]. Washington clinical sites, including infusion centers at UW Medicine, Swedish Medical Center, and Providence Health, have established inclisiran administration protocols.

What to Expect at Your First Leqvio Appointment in Washington

The first clinical visit for inclisiran in Washington is primarily a prescriber consultation. Expect a thorough cardiovascular risk assessment, a review of your lipid history, and a discussion of why inclisiran is being chosen over or added to other PCSK9-inhibiting options. The ACC/AHA 2018 Cholesterol Guideline recommends that clinicians discuss the net benefit, potential adverse effects, and cost before initiating any PCSK9-targeted therapy [13].

Adverse effects from inclisiran are mild. Injection site reactions (pain, erythema, rash) occurred in 8.2% of inclisiran-treated patients versus 1.8% in placebo in the pooled ORION analysis, and no serious injection site reactions were reported [2]. Limb pain was noted as a mild adverse event in 5.1% of treated patients. No significant changes in liver enzymes, renal function, or platelet count were observed versus placebo [9].

Your prescriber will submit the PA during or immediately after the visit. Most Washington specialty pharmacies report a 3 to 10 business day window from PA approval to drug shipment. The clinical site administering the injection then contacts you to schedule. First-dose patients should allow 30 to 90 minutes at the clinical site for the injection (which itself takes under 5 minutes) and a brief post-injection observation period.

How to Transfer an Existing Leqvio Prescription to Washington

Patients relocating to Washington with an active inclisiran prescription from another state face a specific logistics question. The prescription itself transfers through the specialty pharmacy network, since Accredo, CVS Specialty, and similar national pharmacies operate across state lines. Contact the specialty pharmacy with your Washington address update and your new Washington-licensed prescriber's information.

The new prescriber must independently assess your clinical history, review your most recent LDL-C, and sign off on ongoing therapy before the pharmacy will ship in Washington. This is a Washington State prescribing requirement, not a pharmacy policy. The new prescriber will also need to file a fresh PA with your Washington insurer if your coverage changed with the move [10].

If your dosing schedule lands during the transition period, communicate the expected injection date to both your prior prescriber and your new Washington provider to avoid a gap that would require reloading. The permissible dosing window is plus or minus 3 months from the scheduled date; missing that window by more than 3 months resets the Day 1 / Day 90 loading sequence [12].

Costs, Copays, and Patient Assistance Programs in Washington

The list price for inclisiran is approximately $3,500 per dose (two doses per year), placing annual drug costs around $7,000 before insurer negotiation and rebates. Most Washington commercial plan members with approved PAs pay specialty tier copays ranging from $50 to $150 per injection after reaching their deductible.

Novartis operates the Leqvio Co-Pay Assistance Program for commercially insured, eligible patients in Washington. Qualifying patients may pay as little as $0 per injection with copay assistance applied [14]. The program does not apply to government-funded insurance (Medicare Part D, Medicaid, TRICARE), where separate patient assistance programs exist.

The Novartis Patient Assistance Foundation (NPAF) covers inclisiran for uninsured or underinsured patients who meet income criteria, generally at or below 400% of the federal poverty level [14]. Washington residents applying to NPAF should have their prescriber submit the application, which includes income verification, insurance status documentation, and a signed enrollment form.

Monitoring After Starting Leqvio in Washington

LDL-C should be rechecked at approximately 90 days after the first injection to confirm therapeutic response before the Day 90 injection. A second check at 6 months establishes steady-state LDL-C reduction. The ACC/AHA 2022 guidance recommends a target LDL-C of below 70 mg/dL for very high-risk ASCVD and below 100 mg/dL for high-risk patients, with consideration of further intensification if targets are not met [3].

Liver function tests at 3 months and 12 months are a reasonable monitoring protocol given the hepatic mechanism, although no specific monitoring interval is mandated in the Leqvio prescribing information [12]. Renal function monitoring is similarly not mandated but is clinically sensible in patients with baseline chronic kidney disease, as LDL reduction may modify cardiovascular risk calculations in CKD [15].

Annual lipid panels replace the more frequent monitoring required with statins during dose titration, since inclisiran's effect is stable after the loading phase. Washington Apple Health requires annual lipid panel documentation to continue PA approval for the second year of therapy [5].